



Fig. 2





Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val Asp Glu Gly Ala Pro Gly Lys Glm Ala Ala Ala Gln Pro Bis Thr Glu Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ire Gly Asp Thr Pro Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val Ser Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly Ala Asp Gly Lys Thr Lys lle Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg [Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Ser Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gln Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile Glu Thr His Lys Leu Thr Phe Arq Glu Asn Ala Lys Ala Lys Thr Asp His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser Gly Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser Ile Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val Ser Ala Ser Leu Ala Lys Gln Gly Leu (SEQ ID NO:71)

Fig. 5





Fig. 6

%00	Peptide 4LM C.O.<=-0.31 NC 40, 58% AD 29, 42%	Peptide 3LM C.O.<=-0.08 NC 23, 48% AD 25, 52%	9.4LM Peptide 3LM C.O. =-0.53 29% NC 16, 67% AD 8, 33% Triminal Node Peptide 8LMRV 9 C.O. =-0.14 NC 11, 92% AD 7, 589%	Terminal Node 10 11 Node 10 12, 22% NC 3, 100% AD 7, 77% AD 0, 0%
AD 48, 50%	7	Peptide 3LM C.O.<=0.47 NC 17, 81% AD 4, 19%	Terminal Node Terminal Node Peptide NC 17, 90% NC 0, 0% NC 7, AD 2, 10% AD 2, 100% AD 17, Co. <	Terminal Node Terminal Node 6
	Peptide 8LMR C.O.<=0.458 NC 8, 30% AD 19, 70%	Terminal Node Peptide 4LM 1 1 1 1 1 1 1 1 1	Terminal Node 2 3 NC 8, 72% NC 9, 0% AD 3, 27% AD 2, 100%	Fig. 7

Antibody profiles characteristic for AD or NC sera






Fig. 9